In summary, SS-b1 and SS-d inhibit ferrodystrophy by activating the NRF2/HO-1 pathway, demonstrating significant therapeutic effects on DSS-induced colitis which demonstrates the potential of SS-d in the treatment of colitis and its clinical application value. Here, HMOX1 is linked to colitis.